PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))))) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI). Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
Transphorm And Allegro MicroSystems Team Up To Increase GaN Power System Performance For High Power Applications
Purpose-Built Isolated Gate Drivers Enable Rapid Adoption of Advanced GaN Semiconductors in Data Centers, Renewables, Electric VehiclesTransphorm, Inc. (NASDAQ:TGAN), a global leader in robust GaN power semiconductors,
